{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:32:14Z","timestamp":1788877934170,"version":"build-2803163510"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding toward endocrinology. The EndoCompass project\u2014a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in pituitary and neuroendocrine tumor endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Research priorities encompass congenital and acquired disorders, tumor development and progression, and neuroendocrine neoplasms. Key areas include genetic\/epigenetic factors, tumor microenvironment, personalized treatment approaches, developing preclinical models, and implementing artificial intelligence. Special emphasis is placed on aggressive tumors, hypothalamic syndromes, and establishing pan-European biobanks and databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into pituitary-neuroendocrine disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf035","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:01:57Z","timestamp":1760691717000},"page":"ii84-ii96","source":"Crossref","is-referenced-by-count":4,"title":["EndoCompass project: research roadmap for pituitary and neuroendocrine tumor endocrinology"],"prefix":"10.1093","volume":"193","author":[{"given":"Justo P","family":"Castano","sequence":"first","affiliation":[{"name":"Department of Cell Biology, Physiology, and Immunology, University of C\u00f3rdoba, Cordoba 14004 ,","place":["Spain"]},{"name":"Maimonides Biomedical Research Institute of Cordoba, C\u00f3rdoba 14004 ,","place":["Spain"]},{"name":"Reina Sofia University Hospital, C\u00f3rdoba 14004 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul Tulsidas","family":"Dattani","sequence":"additional","affiliation":[{"name":"Genetics and Genomic Medicine Programme, UCL GOS Institute of Child Health, London ,","place":["United Kingdom"]},{"name":"Endocrinology Department, Great Ormond Street Hospital For Children NHS Trust, London, WC1N 3JH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Division of Medicine, Hadassah University Hospital and Faculty of Medicine, the Hebrew University, Jerusalem, 91120 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research, University of Birmingham, and Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham B15 2TT ,","place":["UK"]},{"name":"Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne E","family":"Pavel","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 1, Schwerpunkt Endokrinologie und Diabetologie, Uniklinikum Erlangen, ENETS Center of Excellence Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Ulmenweg 18, 91054, Erlangen, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Andoniadou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Carl Gustav Carus, Department of Medicine III, Technische Universit\u00e4t Dresden, Dresden ,","place":["Germany"]},{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystallenia","family":"Alexandraki","sequence":"additional","affiliation":[{"name":"2nd Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Capatina","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest 050474 \u00a0","place":["Romania"]},{"name":"Department of Pituitary and Neuroendocrine Pathology, C.I. Parhon National Institute of Endocrinology, Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3472-0746","authenticated-orcid":false,"given":"Manuela","family":"Cerbone","sequence":"additional","affiliation":[{"name":"Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Hospital for Children, London, WC1N 1EH ,","place":["United Kingdom"]},{"name":"Department of Endocrinology, Great Ormond Street Hospital for Children, London WC1N 3JH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[{"name":"Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, 16132 Genova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoong-Wei","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Great Ormond Street Hospital for Children, London WC1N 3JH ,","place":["United Kingdom"]},{"name":"Genetics and Genomic Medicine Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J","family":"Hofland","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ibanez-Costa","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology, and Immunology, University of C\u00f3rdoba, Cordoba 14004 ,","place":["Spain"]},{"name":"Maimonides Biomedical Research Institute of Cordoba, C\u00f3rdoba 14004 ,","place":["Spain"]},{"name":"Reina Sofia University Hospital, 14004 C\u00f3rdoba ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-7258","authenticated-orcid":false,"given":"Mirela-Diana","family":"Ilie","sequence":"additional","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, 69008 Lyon ,","place":["France"]},{"name":"Endocrinology Department, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863, Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":false,"given":"Andrea M","family":"Isidori","sequence":"additional","affiliation":[{"name":"Section of Medical Pathophysiology and Endocrinology, Department of Experimental Medicine, Sapienza University of Rome, Rome 00161 ,","place":["Italy"]},{"name":"Endocrine and Andrological Regional Rare Disease Center (Endo-ERN accredited), Policlinico Umberto I, Rome 00161 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Korbonits","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ ,","place":["United Kingdom"]},{"name":"William Harvey Research Institute, London EC1M 6BQ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kos-Kud\u0142a","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice 40-055, Silesian Voivodeship ,","place":["Poland"]},{"name":"Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice 40-055, Silesian Voivodeship ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-5238","authenticated-orcid":false,"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"Pediatric Clinic and Endocrinology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa 16147 ,","place":["Italy"]},{"name":"DINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, 16132 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3886","authenticated-orcid":false,"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan 20122, Lombardy ,","place":["Italy"]},{"name":"Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Lombardy ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Marazuela","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Madrid, Department of Endocrinology and Nutrition, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Madrid 28006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospices civils de Lyon, Reference Centre for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est,\u201d Bron 69500 ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universite Claude Bernard Lyon 1-Domaine de Rockefeller institution, Lyon 69373 ,","place":["France"]},{"name":"Cancer Research Centre Lyon, Inserm U1052, CNRC UMR5286, Lyon, Auvergne-Rh\u00f4ne-Alpes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[{"name":"Medizinische Klinik & Poliklinik IV, LMU Klinikum M\u00fcnchen, Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4374","authenticated-orcid":false,"given":"Marily","family":"Theodoropoulou","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich, Ziemssenstra\u00dfe 5, Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke M","family":"van Santen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht 3508 AB ,","place":["Netherlands"]},{"name":"Division of Pediatric Oncology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht 3720 AC, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[{"name":"Section of Endocrinology & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara 44121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101705015450000_lvaf035-B1","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"2025101705015450000_lvaf035-B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1-2","key":"2025101705015450000_lvaf035-B3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.mce.2007.10.006","article-title":"The role of somatostatin analogues in the treatment of neuroendocrine tumours","volume":"286","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"2025101705015450000_lvaf035-B4","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025101705015450000_lvaf035-B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","article-title":"A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis","volume":"12","author":"Ho","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2025101705015450000_lvaf035-B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41574-023-00948-8","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 1, general recommendations","volume":"20","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2025101705015450000_lvaf035-B7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025101705015450000_lvaf035-B8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41574-024-01010-x","article-title":"Evidence for somatic mutation screening on aggressive prolactinomas","volume":"20","author":"Theodoropoulou","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2025101705015450000_lvaf035-B9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2025101705015450000_lvaf035-B10","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.arcmed.2023.102915","article-title":"Genomics, transcriptomics, and epigenetics of sporadic pituitary tumors","volume":"54","author":"Marrero-Rodr\u00edguez","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"2025101705015450000_lvaf035-B11","doi-asserted-by":"publisher","first-page":"e13233","DOI":"10.1111\/jne.13233","article-title":"New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)","volume":"35","author":"Angelousi","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2025101705015450000_lvaf035-B12","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.beem.2020.101432","article-title":"Genetic forms of neurohypophyseal diabetes insipidus","volume":"34","author":"Spiess","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025101705015450000_lvaf035-B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr Rev"},{"issue":"10","key":"2025101705015450000_lvaf035-B14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cancers11101605","article-title":"The microenvironment of pituitary tumors-biological and therapeutic implications","volume":"11","author":"Ilie","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2025101705015450000_lvaf035-B15","doi-asserted-by":"publisher","first-page":"e13052","DOI":"10.1111\/jne.13052","article-title":"The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours","volume":"33","author":"Marques","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"2025101705015450000_lvaf035-B16","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.yfrne.2020.100852","article-title":"The tumour microenvironment of pituitary neuroendocrine tumours","volume":"58","author":"Marques","year":"2020","journal-title":"Front Neuroendocrinol"},{"issue":"3","key":"2025101705015450000_lvaf035-B17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","article-title":"The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications","volume":"25","author":"Marques","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"2025101705015450000_lvaf035-B18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.17925\/EE.2023.19.2.12","article-title":"Prognostic biomarkers in pituitary tumours: a. systematic review","volume":"19","author":"Papadimitriou","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"1","key":"2025101705015450000_lvaf035-B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"12","key":"2025101705015450000_lvaf035-B20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025101705015450000_lvaf035-B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11102-023-01305-8","article-title":"Refractory lactotroph adenomas","volume":"26","author":"Urwyler","year":"2023","journal-title":"Pituitary"},{"issue":"2","key":"2025101705015450000_lvaf035-B22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas","volume":"21","author":"Ntali","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2025101705015450000_lvaf035-B23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-018-0863-9","article-title":"Mortality in patients with non-functioning pituitary adenoma","volume":"21","author":"Tampourlou","year":"2018","journal-title":"Pituitary"},{"issue":"6","key":"2025101705015450000_lvaf035-B24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025101705015450000_lvaf035-B25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"2025101705015450000_lvaf035-B26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2025101705015450000_lvaf035-B27","doi-asserted-by":"publisher","first-page":"dgaa497","DOI":"10.1210\/clinem\/dgaa497","article-title":"Treatment options for gonadotroph tumors: current state and perspectives","volume":"105","author":"Ilie","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025101705015450000_lvaf035-B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025101705015450000_lvaf035-B29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2025101705015450000_lvaf035-B30","doi-asserted-by":"publisher","first-page":"13148","DOI":"10.1111\/jne.13148","article-title":"Genetics of Cushing's disease","volume":"34","author":"Simon","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2025101705015450000_lvaf035-B31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1210\/jc.2018-02080","article-title":"Tumor-directed therapeutic targets in Cushing disease","volume":"104","author":"Theodoropoulou","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025101705015450000_lvaf035-B32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2025101705015450000_lvaf035-B33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"4","key":"2025101705015450000_lvaf035-B34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"issue":"12","key":"2025101705015450000_lvaf035-B35","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/cancers11121936","article-title":"Pituitary adenomas and invasiveness from anatomo-surgical, radiological, and histological perspectives: a systematic literature review","volume":"11","author":"Serioli","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025101705015450000_lvaf035-B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2025101705015450000_lvaf035-B37","doi-asserted-by":"publisher","first-page":"220338","DOI":"10.1530\/ERC-22-0338","article-title":"Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review","volume":"30","author":"Raymond","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025101705015450000_lvaf035-B38","doi-asserted-by":"publisher","first-page":"dgaz184","DOI":"10.1210\/clinem\/dgz184","article-title":"The molecular basis of congenital hypopituitarism and related disorders","volume":"105","author":"Gregory","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025101705015450000_lvaf035-B39","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.gim.2023.100881","article-title":"Identification of genetic variants and phenotypic characterization of a large cohort of patients with congenital hypopituitarism and related disorders","volume":"25","author":"Gregory","year":"2023","journal-title":"Genet Med"},{"key":"2025101705015450000_lvaf035-B40","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.eclinm.2019.11.017","article-title":"Endocrine morbidity in midline brain defects: differences between septo-optic dysplasia and related disorders","volume":"19","author":"Cerbone","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2025101705015450000_lvaf035-B41","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1210\/jc.2015-2028","article-title":"Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years","volume":"100","author":"Gan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025101705015450000_lvaf035-B42","doi-asserted-by":"publisher","first-page":"lvad027","DOI":"10.1093\/ejendo\/lvad027","article-title":"Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage","volume":"188","author":"Beckhaus","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025101705015450000_lvaf035-B43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2213-8587(23)00162-6","article-title":"National UK guidelines for the management of paediatric craniopharyngioma","volume":"11","author":"Gan","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2025101705015450000_lvaf035-B44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2352-4642(21)00088-2","article-title":"Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline","volume":"5","author":"Cerbone","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"2025101705015450000_lvaf035-B45","doi-asserted-by":"publisher","first-page":"lvad009","DOI":"10.1093\/ejendo\/lvad009","article-title":"Diagnostic criteria for the hypothalamic syndrome in childhood","volume":"188","author":"van Santen","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025101705015450000_lvaf035-B46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1210\/endrev\/bnad033","article-title":"Appetite- and weight-regulating neuroendocrine circuitry in hypothalamic obesity","volume":"45","author":"Gan","year":"2024","journal-title":"Endocr Rev"},{"issue":"1","key":"2025101705015450000_lvaf035-B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"van Iersel","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"2025101705015450000_lvaf035-B48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","article-title":"Hypothalamic syndrome","volume":"8","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2025101705015450000_lvaf035-B49","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2025101705015450000_lvaf035-B50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/B978-0-12-800870-6.00010-8","volume-title":"Image-Guided Neurosurgery; Chapter 10","author":"Bi","year":"2015"},{"issue":"1","key":"2025101705015450000_lvaf035-B51","doi-asserted-by":"publisher","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"2025101705015450000_lvaf035-B52","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.nec.2012.06.008","article-title":"Endoscopic surgery for pituitary tumors","volume":"23","author":"Lucas","year":"2012","journal-title":"Neurosurg Clin N Am"},{"issue":"4","key":"2025101705015450000_lvaf035-B53","doi-asserted-by":"publisher","first-page":"104079","DOI":"10.1016\/j.lpm.2021.104079","article-title":"Pituitary surgery","volume":"50","author":"Mortini","year":"2021","journal-title":"Presse Med"},{"issue":"2","key":"2025101705015450000_lvaf035-B54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11102-019-01003-4","article-title":"Common tools for pituitary adenomas research: cell lines and primary cells","volume":"23","author":"Zhu","year":"2020","journal-title":"Pituitary"},{"issue":"8","key":"2025101705015450000_lvaf035-B55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/ERC-22-0088","article-title":"Improved pasireotide response in USP8 mutant corticotroph tumours in vitro","volume":"29","author":"Albani","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2025101705015450000_lvaf035-B56","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A somatostatin receptor subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors","volume":"26","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025101705015450000_lvaf035-B57","doi-asserted-by":"publisher","first-page":"1233714","DOI":"10.3389\/fendo.2023.1233714","article-title":"Organoid models of the pituitary gland in health and disease","volume":"14","author":"Laporte","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025101705015450000_lvaf035-B58","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1210\/clinem\/dgae228","article-title":"Establishment of human pituitary neuroendocrine tumor derived organoid and its pilot application for drug screening","volume":"110","author":"Cui","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025101705015450000_lvaf035-B59","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.stemcr.2023.02.006","article-title":"Generation of hypothalamic neural stem cell-like cells in vitro from human pluripotent stem cells","volume":"18","author":"Miwata","year":"2023","journal-title":"Stem Cell Reports"},{"issue":"3","key":"2025101705015450000_lvaf035-B60","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1530\/JOE-18-0571","article-title":"Mouse models in endocrine tumors","volume":"240","author":"Gahete","year":"2018","journal-title":"J Endocrinol"},{"issue":"2","key":"2025101705015450000_lvaf035-B61","doi-asserted-by":"publisher","first-page":"025011","DOI":"10.1088\/1758-5090\/ad22f1","article-title":"A microscale 3D organ on a chip for recapitulating reciprocal neuroendocrine crosstalk between the hypothalamus and the pituitary gland","volume":"16","author":"Park","year":"2024","journal-title":"Biofabrication"},{"issue":"2","key":"2025101705015450000_lvaf035-B62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11102-023-01369-6","article-title":"Current status of artificial intelligence technologies in pituitary adenoma surgery: a scoping review","volume":"27","author":"Maroufi","year":"2024","journal-title":"Pituitary"},{"issue":"7","key":"2025101705015450000_lvaf035-B63","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025101705015450000_lvaf035-B64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000481390","article-title":"Neuroendocrine neoplasms: dichotomy, origin and classifications","volume":"33","author":"Kl\u00f6ppel","year":"2017","journal-title":"Visc Med"},{"issue":"1","key":"2025101705015450000_lvaf035-B65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2025101705015450000_lvaf035-B66","doi-asserted-by":"publisher","first-page":"780716","DOI":"10.3389\/fonc.2022.780716","article-title":"Biomarker landscape in neuroendocrine tumors with high-grade features: current knowledge and future perspective","volume":"12","author":"Prisciandaro","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2025101705015450000_lvaf035-B67","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2018-00160","article-title":"Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms","volume":"40","author":"Mafficini","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"2025101705015450000_lvaf035-B68","doi-asserted-by":"publisher","first-page":"e230003","DOI":"10.1530\/EO-23-0003","article-title":"The role of DNA methylation in human pancreatic neuroendocrine tumours","volume":"3","author":"English","year":"2023","journal-title":"Endocr Oncol"},{"issue":"3","key":"2025101705015450000_lvaf035-B69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/endrev\/bnad034","article-title":"The molecular biology of midgut neuroendocrine neoplasms","volume":"45","author":"Webster","year":"2024","journal-title":"Endocr Rev"},{"issue":"2","key":"2025101705015450000_lvaf035-B70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1507\/endocrj.EJ23-0457","article-title":"Single-cell and spatial transcriptomics in endocrine research","volume":"71","author":"Matsumoto","year":"2024","journal-title":"Endocr J"},{"issue":"22","key":"2025101705015450000_lvaf035-B71","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.3390\/cancers14225646","article-title":"Preclinical models of neuroendocrine neoplasia","volume":"14","author":"Sedlack","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2025101705015450000_lvaf035-B72","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.ccell.2023.11.007","article-title":"Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites","volume":"41","author":"Dayton","year":"2023","journal-title":"Cancer Cell"},{"key":"2025101705015450000_lvaf035-B73","doi-asserted-by":"publisher","first-page":"627819","DOI":"10.3389\/fendo.2021.627819","article-title":"Patient-derived organoid models of human neuroendocrine carcinoma","volume":"12","author":"Dijkstra","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025101705015450000_lvaf035-B74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7150\/thno.90093","article-title":"Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues","volume":"14","author":"Hwangbo","year":"2024","journal-title":"Theranostics"},{"issue":"5","key":"2025101705015450000_lvaf035-B75","doi-asserted-by":"publisher","first-page":"101796","DOI":"10.1016\/j.beem.2023.101796","article-title":"Tyrosine kinase inhibitors and immunotherapy updates in neuroendocrine neoplasms","volume":"37","author":"Mosalem","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2025101705015450000_lvaf035-B76","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.3390\/curroncol30090627","article-title":"Narrative review of immunotherapy in gastroentero-pancreatic neuroendocrine neoplasms","volume":"30","author":"Kaur","year":"2023","journal-title":"Curr Oncol"},{"key":"2025101705015450000_lvaf035-B77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2023.03.024","article-title":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","volume":"186","author":"Boil\u00e8ve","year":"2023","journal-title":"Eur J Cancer"},{"issue":"24","key":"2025101705015450000_lvaf035-B78","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.3390\/cancers15245892","article-title":"Determinants affecting the clinical implementation of a molecularly informed molecular tumor board recommendation: experience from a tertiary cancer center","volume":"15","author":"T\u00f6gel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025101705015450000_lvaf035-B79","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2025101705015450000_lvaf035-B80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"issue":"4","key":"2025101705015450000_lvaf035-B81","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025101705015450000_lvaf035-B82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1210\/endrev\/bnad035","article-title":"What is carcinoid syndrome? A critical appraisal of its proposed mediators","volume":"45","author":"Mulders","year":"2024","journal-title":"Endocr Rev"},{"issue":"4","key":"2025101705015450000_lvaf035-B83","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2013'Something in the way it moves\u2019","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii84\/64633662\/lvaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii84\/64633662\/lvaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:01:58Z","timestamp":1760691718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/Supplement_2\/ii84\/8281954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":83,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf035","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}